Depression Treatment Market is anticipated to grow at a CAGR of 4.1% during the forecast period. The increasing number of FDA approvals for antidepressants along with the expansion in pipeline products by key market players is certain factors driving the growth of the depression treatment industry.
In February 2021, Zydus Cadila has received US FDA approval for Nortriptyline Hydrochloride Capsules USP. The capsules come up in the strength of 10 mg, 25 mg, 50 mg, and 75 mg. Nortriptyline Hydrochloride Capsules USP is majorly used for the treatment of depression.
Moreover, in July 2020, VistaGen Therapeutics, a US-based biopharmaceutical company had received US FDA approval for PH94B under Phase 3 development to treat acute anxiety and mental illness in adult patients with a social anxiety disorder (SAD). PH94B is an investigational rapid-onset neurosteroid nasal spray majorly used for the treatment of social anxiety disorder.
Furthermore, in March 2019, Johnson & Johnson’s ketamine-derived nasal spray Spravato for treatment-resistant depression has been approved by the FDA. The Spravato CIII Nasal Spray is used for the treatment of depressive disorder in adults with a high risk of major depressive disorder (MDD). Thus, these approvals by the FDA for antidepressant drugs produced by major key players, the depression treatment market is expected to witness significant growth during the forecast period.
To Request a Sample of our Report on Depression Treatment Market: https://www.omrglobal.com/request-sample/depression-treatment-market
Market Coverage
- The market number available for – 2021-2029
- Base year- 2021
- Forecast period- 2023-2029
Segment Covered-
- By Drug Type
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape- Eli Lilly and Company, Pfizer, Inc., Johnson & Johnson, Merck & Co., Inc., H. Lundbeck A/S, F. Hoffmann-La Roche Ltd, and Others.
Depression Treatment Market Report Segment
By Drug Type
- Selective Serotonin Reuptake Inhibitors
- Tricyclic Antidepressants
- Serotonin-Norepinephrine Reuptake Inhibitors
- Monoamine Oxidase Inhibitors
- Others
A full report of Depression Treatment Market is available at: https://www.omrglobal.com/industry-reports/depression-treatment-market
Depression Treatment Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Alkermes Plc
- Allergen Plc
- AstraZeneca plc
- Bausch Health Companies, Inc.
- Eli Lilly and Co.
- Hoffmann-La Roche AG
- Garmin Ltd.
- GlaxoSmithKline plc
- Lundbeck A/S
- Johnson & Johnson Services, Inc.
- Lief Therapeutics
- Lupin Ltd.
- MagVenture, Inc.
- Mylan N.V.
Reasons to Buy From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
